-
2022 China Pharmaceutical Industry Technology Annual Conference Schedule Update
Time of Update: 2022-09-06
All relevant units: In order to implement the "14th Five-Year Plan" development plan of the national pharmaceutical industry, promote the innovation-driven transformation of the pharmaceutical industr
-
Hold hands with Lilly
Time of Update: 2022-05-26
On March 28, Innovent and Eli Lilly jointly announced that the two parties will deepen their strategic cooperation and have reached an agreement on the following matters: 1) Innovent obtains access to
-
Shuanghe Pharmaceutical, a wholly-owned subsidiary of China Resources Double Crane, passed the CDE technical review for the API of ticagrelor
Time of Update: 2022-05-02
On February 23, China Resources Double-Crane announced that its wholly-owned subsidiary, Double-Crane Pharmaceutical Co. , Ltd. , passed the technical review of the Drug Evaluation Center of the State
-
Current progress in the treatment of primary Sjogren's syndrome
Time of Update: 2021-12-06
Because pro-inflammatory cytokines such as interleukin-6 (IL-6) play a key role in B cell activation and participate in the pathogenesis of pSS, they target Biological preparations of these cytokines may have potential benefits in the treatment of pSS .
-
Fosun Pharma’s holding subsidiary withdraws the registration application for cromolyn sodium granules
Time of Update: 2021-12-04
As of the date of this announcement, cromolyn sodium oral preparations that have been marketed globally mainly include Sanofi's INTAL®, etc.
-
A pharmaceutical company was punished for using unqualified Chinese medicinal materials to produce
Time of Update: 2021-12-03
According to the administrative penalty decision, the type of administrative punishment for a pharmaceutical company in Fujian for the production and sale of inferior drugs such as Baixian Pi, Qianhu, and Epimedium and according to relevant regulations, the Office decided to impose the following penalties on the parties: The Office ordered the parties immediately Corrected illegal activities, confiscated 2 kilograms of inferior medicine Qianhu, 12.
-
Chain giants have a new acquisition
Time of Update: 2021-10-20
According to relevant data, the number of Yifeng stores in Central and South China has increased from 559 in 2015 to 2,858 by the end of 2020, an increase of more than 2,000 in five years .
-
CSCO 2021: Professor Shukui Qin reports that the first-line treatment of Akoladine has a heavier baseline and a poorer prognosis for advanced hepatocellular carcinoma
Time of Update: 2021-09-29
manageAt the just-opening CSCO conference, in the theme report of the conference, Professor Qin Shukui brought us the latest research in the field of liver cancer, that is, "Acoradine first-line treatment with a heavier baseline and a poor prognosis for advanced hepatocellular carcinoma is a multi-center, randomized , Dual-simulation Phase III clinical study results: Marker enrichment design, overall survival, quality of life and safety" .
-
Clinical value orientation makes doctors a part of the pharmaceutical industry chain
Time of Update: 2021-09-20
At the China International Trade Fair on Clinical Oncology and Anti-tumor Drug Innovation and Research Forum held recently, the participating experts agreed that clinical value-oriented anti-tumor drug research and development is an important development direction, and first-line doctors or professors should Actively become a link in the pharmaceutical industry chain .
-
Sanofi Pompe bay disease therapy is eligible for FDA priority review
Time of Update: 2021-03-05
, Sanofi announced that the U.S. FDA has accepted the company's Biological Products Licensing Application (BLA) for avalglucosidase alfa for the treatment of glycogen accumulation disease (I.
A key double-blind drug-controlled Phase 3 clinical trial assessed the safety and efficacy of avalglucosidase alfa compared to α-glucosidease (standard treatment) in patients with late-haired Pompeidase.
-
Drug enterprise risk warning issued 33 pharmaceutical companies on the list
Time of Update: 2021-02-24
2, Shandong Weizhi Encycloddic Pharmaceutical Co., Ltd. the company produced hydrochloric acid Lidokain injection, "check" item "visible foreign body" does not meet the standard provisions, Shandong Provincial Drug Administration issued a decision on administrative punishment, fined about 495,000 yuan.
-
A magenta pharmaceutical coin-acid klinmycin capsule has been approved for listing
Time of Update: 2020-08-14
Guide: Phlinmycin capsules are suitable for serious infections caused by sensitive anaerobic bacteria and severe infections caused by sensitive strains such as streptococcus, pneumococcal and staphylococcus.
-
AbbVie, New Base II JAK inhibitorapproved on the same day to treat rheumatoid arthritis and bone marrow fibrosis, respectively
Time of Update: 2020-06-08
Inrebic, the first new drug for bone marrow fibrosis in nearly a decade, FDA approves inrebic treatment for patients with pre-intermediate-2 and high-risk (intermediate-2/high-risk) primary or second
-
What has been adjusted in the work plan of national health insurance catalog adjustment in 2019
Time of Update: 2019-04-18
Yesterday (April 17), the State Medical Insurance Bureau officially announced the work plan for 2019 national medical insurance catalog adjustment (hereinafter referred to as the "work plan") on its o
-
Pain points in innovative drug research and development of domestic pharmaceutical enterprises
Time of Update: 2018-09-03
"It's a pleasure that the good research results of the original drugs in our country are constantly recognized and published At the same time, we should feel that there is still room for efforts betwe
